Design controls require you to monitor post-market performance. Where exactly does external signal data fit in your design inputs? You're likely reviewing predicate devices or updating risk management

Here's what's happening right now: 391 new FDA recalls were issued this week, including 5 new signals from Health Canada. Key examples include convenience kits for dialysis maintenance (e.g., Medline ADD A CATH DIALYSIS KIT, Centurion CENTRAL LINE INSERTION TRAY) due to silicone seal issues causing occluded fluid paths, and orthopedic implants like the Reverse Shoulder Prosthesis and EMPOWR 3D KNEE with incorrect labeling. Additionally, there are 26,000 new FDA Adverse Event Reports (MAUDE/MDRs) and 194 new Health Canada mdl signals, totaling 26,590 new signals today.

For design engineers, this data is critical for predicate device selection and risk analysis under ISO 14971. The dialysis kit recalls highlight material failure modes—silicone seal doming and tearing—that should inform your design inputs for similar fluid-handling components. The labeling errors in implants underscore the importance of process controls in 21 CFR 820.30 design controls, suggesting a trend where post-market data reveals gaps in verification steps.

We analyzed this across 548,000+ regulatory records and found that recurring issues in kits and implants often stem from inadequate validation of supplier components or labeling processes, impacting competitor landscapes and risk profiles.

See how these signals map to your product codes and inform design decisions at truemeddevice.com.